While revenue reflects how well a company’s products are selling, profit is the financial metric that really matters. It tells investors how efficiently a company is managed and how healthy the business is overall. We’ve taken a look at these bottom line figures and compiled a list of the top 10 most profitable pharma companies. But that's not all. The FDA advisory committee meeting met last Thursday and Friday, and the stakes were high. Bluebird bio came away on top. The committee endorsed two of its gene therapy candidates. Lastly, we’re all celebrating here at Fierce because our team’s faces are plastered on billboards at BIO International Convention. And we sent one shoe-leather reporter on a wild goose chase to find them. 

To learn more about the topics in this episode: 
The top 10 most profitable pharma companies in 2021
Pfizer already agreed to delay supply of COVID-19 shots to EU, now the bloc wants more
GSK hails phase 3 win for RSV vaccine in older adults, sparking race to regulators
Rune Labs translates Apple Watch data into Parkinson's insights with FDA nod
Bluebird gene therapy overcomes safety worries to snag a win at FDA advisory panel
Bluebird scores 2nd straight win at high-stakes FDA gene therapy meeting
Amid FDA delay, Amylyx scores conditional ALS drug nod in Canada
Eli Lilly's Olumiant snags biopharma's first FDA green light for alopecia areata
Alnylam's next-gen RNA drug Amvuttra wins FDA approval—and a Pfizer showdown may await
Ekso Bionics nabs FDA exoskeleton clearance for multiple sclerosis rehabilitation
Pfizer gives up on Paxlovid in less vulnerable COVID patients after data fail to impress

The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. 

While revenue reflects how well a company&rsquo;s products are selling, profit is the financial metric that really matters. It tells investors how efficiently a company is managed and how healthy the business is overall. We&rsquo;ve taken a look at these bottom line figures and compiled a list of the top 10 most profitable pharma companies. But that's not all.&nbsp;The FDA advisory committee meeting met last Thursday and Friday, and the stakes were high. Bluebird bio came away on top. The committee endorsed two of its gene therapy candidates. Lastly, we&rsquo;re all celebrating here at Fierce because our team&rsquo;s faces are plastered on billboards at BIO International Convention. And we sent one shoe-leather reporter on a wild goose chase to find them.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/special-reports/top-10-most-profitable-pharma-companies-2021" data-cke-saved-href="https://www.fiercepharma.com/special-reports/top-10-most-profitable-pharma-companies-2021">The top 10 most profitable pharma companies in 2021</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-already-agreed-delay-supply-covid-19-shots-eu-now-bloc-wants-more" data-cke-saved-href="https://www.fiercepharma.com/pharma/pfizer-already-agreed-delay-supply-covid-19-shots-eu-now-bloc-wants-more">Pfizer already agreed to delay supply of COVID-19 shots to EU, now the bloc wants more</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/gsk-hails-phase-3-win-rsv-vaccine-older-adults-sparking-race-regulators" data-cke-saved-href="https://www.fiercebiotech.com/biotech/gsk-hails-phase-3-win-rsv-vaccine-older-adults-sparking-race-regulators">GSK hails phase 3 win for RSV vaccine in older adults, sparking race to regulators</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/rune-labs-translates-apple-watch-data-parkinsons-insights-fda-nod" data-cke-saved-href="https://www.fiercebiotech.com/medtech/rune-labs-translates-apple-watch-data-parkinsons-insights-fda-nod">Rune Labs translates Apple Watch data into Parkinson's insights with FDA nod</a></li>
<li><a href="https://www.fiercepharma.com/pharma/fda-panel-decision-bluebird-eli-cel" data-cke-saved-href="https://www.fiercepharma.com/pharma/fda-panel-decision-bluebird-eli-cel">Bluebird gene therapy overcomes safety worries to snag a win at FDA advisory panel</a></li>
<li><a href="https://www.fiercepharma.com/pharma/bluebird-scores-second-straight-win-high-stakes-fda-gene-therapy-meeting" data-cke-saved-href="https://www.fiercepharma.com/pharma/bluebird-scores-second-straight-win-high-stakes-fda-gene-therapy-meeting">Bluebird scores 2nd straight win at high-stakes FDA gene therapy meeting</a></li>
<li><a href="https://www.fiercepharma.com/pharma/amid-fda-delay-amylyx-scores-conditional-als-nod-canada" data-cke-saved-href="https://www.fiercepharma.com/pharma/amid-fda-delay-amylyx-scores-conditional-als-nod-canada">Amid FDA delay, Amylyx scores conditional ALS drug nod in Canada</a></li>
<li><a href="https://www.fiercepharma.com/pharma/eli-lillys-olumiant-snags-first-fda-green-light-alopecia-areata" data-cke-saved-href="https://www.fiercepharma.com/pharma/eli-lillys-olumiant-snags-first-fda-green-light-alopecia-areata">Eli Lilly's Olumiant snags biopharma's first FDA green light for alopecia areata</a></li>
<li><a href="https://www.fiercepharma.com/marketing/alnylams-next-gen-rna-drug-amvuttra-wins-fda-approval-blockbuster-pfizer-showdown-awaits" data-cke-saved-href="https://www.fiercepharma.com/marketing/alnylams-next-gen-rna-drug-amvuttra-wins-fda-approval-blockbuster-pfizer-showdown-awaits">Alnylam's next-gen RNA drug Amvuttra wins FDA approval&mdash;and a Pfizer showdown may await</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/ekso-bionics-nabs-fda-exoskeleton-clearance-multiple-sclerosis-rehabilitation" data-cke-saved-href="https://www.fiercebiotech.com/medtech/ekso-bionics-nabs-fda-exoskeleton-clearance-multiple-sclerosis-rehabilitation">Ekso Bionics nabs FDA exoskeleton clearance for multiple sclerosis rehabilitation</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-stops-paxlovid-work-less-vulnerable-covid-19-patients-after-no-benefit-symptom-relief" data-cke-saved-href="https://www.fiercepharma.com/pharma/pfizer-stops-paxlovid-work-less-vulnerable-covid-19-patients-after-no-benefit-symptom-relief">Pfizer gives up on Paxlovid in less vulnerable COVID patients after data fail to impress</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our &ldquo;Fierce&rdquo; journalists.&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement